Vaxil Bio Ltd is an immuno-oncology biotechnology company. It is principally engaged in research and development of the ImMucin vaccine to treat cancer. ImMucin is the company's immunotherapy product. The organization is focused on developing novel immunotherapies including neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. Its VaxHit platform allows identification, isolation, and production of specific antigen-based immunotherapy products.